ArticleApplied biosafety : journal of the American Biological Safety Association2026
Implementation of a Biorisk Management System in Armenia for ISO 35001:2019 Certification.
Article in Applied biosafety : journal of the American Biological Safety Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Infectious disease outbreaks present significant public health and economic challenges that continue to persist worldwide. Accidental laboratory release or criminal misuse of infectious agents adds to these challenges, underscoring the need for responsible research and adequate biological risk (biorisk) mitigation. Countries such as Armenia that lack comprehensive legal frameworks for biosafety and biosecurity are proactively adopting standards such as International Organization for Standardization (ISO) 35001:2019 to enhance their safety culture and build a strong foundation through a structured Biorisk Management System. This study aimed to evaluate the biorisk management gaps at the Reference Laboratory of Especially Dangerous Pathogens (RLEDP) and implement the necessary steps to achieve ISO 35001:2019 certification. Methods: RLEDP worked with both the Management Systems and Business Consultants to perform a gap analysis of the current situation at RLEDP as it pertains to biorisk management, and with international subject matter experts through the Defense Threat Reduction Agency Biological Threat Reduction Program (BTRP) program to provide guidance and training to assist RLEDP. Results: The gap analysis highlighted areas that needed improvement, such as documentation, risk assessment methodologies, and staff training. The analyses and requirements led to the development and/or finalization of 11 facility-specific documents and the completion of 40 individual training courses for RLEDP staff. This work culminated in the development of a Biorisk Management Plan and ISO 35001:2019 certification. Conclusions: In 2022, RLEDP achieved ISO 35001:2019 certification and passed its first annual audit in 2023, demonstrating its commitment to biosafety and biosecurity. Continuous updates, interdepartmental collaboration, and legislative improvements remain essential for maintaining high standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.